NCT03844464已完成不适用
Special Investigation for LORBRENA Tablets
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 1,290
- 试验地点
- 1
- 主要终点
- Incidence of adverse drug reactions of central nervous system disorder and hepatic dysfunction
研究概览
简要总结
To investigate the following matters under post-marketing use of Lorbrena in patients who received this drug
- Factors affecting the onset of central nervous system disorder
- Effect of Lorbrena in combination with CYP3A inducers on the onset of hepatic dysfunction
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 0 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All administered patients
排除标准
- 未提供
结局指标
主要结局
Incidence of adverse drug reactions of central nervous system disorder and hepatic dysfunction
时间窗: 52 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate CancerProstatic NeoplasmNCT01081873Abbott2,717
已完成
不适用
'OLAP' (OLAparib Regulatory Post-marketing Surveillance)Breast CancerProstate CancerOvarian CancerPancreatic CancerNCT04553926AstraZeneca661
撤回
不适用
Refobacin Revision-3 Bone Cement Post-Market StudyRevision ArthroplastyNCT06699160Zimmer Biomet108
已完成
不适用
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKDPolycystic Kidney, Autosomal DominantNCT02847624Otsuka Pharmaceutical Co., Ltd.1,802
已完成
不适用
Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)ArthritisRheumatoidNCT01230177Pfizer3